A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir

Kenneth Fife, Jennifer Almekinder, Susan Ofner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVES: We conducted this study to compare episodic and suppressive therapy for genital herpes about disease characteristics, disease burden, and psychologic impact. STUDY DESIGN: The authors conducted a randomized, open-label, 1-year treatment trial. RESULTS: Forty subjects were randomized to episodic therapy with valacyclovir (500 mg twice daily for 5 days) and 40 to suppressive therapy (500 mg daily). Subjects in the episodic arm experienced more outbreaks (7.87 ± 4.65) than those in the suppressive arm (1.59 ± 1.93) (P <0.001). Subjects in the episodic arm also had significantly more days with pain and lesions (6.5 ± 7.3) than those in the suppressive arm (1.1 ± 3.3) (P < 0.001), and other quantitative measures of disease burden also favored the suppressive arm. Both treatment groups had significant improvements in their recurrent genital herpes quality-of-life scores from baseline that persisted throughout the study; however, there was no significant difference between the treatment arms in these scores. CONCLUSIONS: Suppressive therapy of recurrent genital herpes with valacyclovir has a greater impact on measures of disease frequency and burden than episodic therapy. However, both treatment strategies lead to significant improvements in recurrent genital herpes quality-of-life scores. Both treatment strategies benefit patients with recurrent genital herpes.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalSexually Transmitted Diseases
Volume34
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

valacyclovir
Herpes Genitalis
Therapeutics
Quality of Life

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)

Cite this

A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. / Fife, Kenneth; Almekinder, Jennifer; Ofner, Susan.

In: Sexually Transmitted Diseases, Vol. 34, No. 5, 05.2007, p. 297-301.

Research output: Contribution to journalArticle

@article{94b184c9ea6244f9bb3643fbd2074e46,
title = "A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir",
abstract = "OBJECTIVES: We conducted this study to compare episodic and suppressive therapy for genital herpes about disease characteristics, disease burden, and psychologic impact. STUDY DESIGN: The authors conducted a randomized, open-label, 1-year treatment trial. RESULTS: Forty subjects were randomized to episodic therapy with valacyclovir (500 mg twice daily for 5 days) and 40 to suppressive therapy (500 mg daily). Subjects in the episodic arm experienced more outbreaks (7.87 ± 4.65) than those in the suppressive arm (1.59 ± 1.93) (P <0.001). Subjects in the episodic arm also had significantly more days with pain and lesions (6.5 ± 7.3) than those in the suppressive arm (1.1 ± 3.3) (P < 0.001), and other quantitative measures of disease burden also favored the suppressive arm. Both treatment groups had significant improvements in their recurrent genital herpes quality-of-life scores from baseline that persisted throughout the study; however, there was no significant difference between the treatment arms in these scores. CONCLUSIONS: Suppressive therapy of recurrent genital herpes with valacyclovir has a greater impact on measures of disease frequency and burden than episodic therapy. However, both treatment strategies lead to significant improvements in recurrent genital herpes quality-of-life scores. Both treatment strategies benefit patients with recurrent genital herpes.",
author = "Kenneth Fife and Jennifer Almekinder and Susan Ofner",
year = "2007",
month = "5",
doi = "10.1097/01.olq.0000237853.69443.71",
language = "English",
volume = "34",
pages = "297--301",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir

AU - Fife, Kenneth

AU - Almekinder, Jennifer

AU - Ofner, Susan

PY - 2007/5

Y1 - 2007/5

N2 - OBJECTIVES: We conducted this study to compare episodic and suppressive therapy for genital herpes about disease characteristics, disease burden, and psychologic impact. STUDY DESIGN: The authors conducted a randomized, open-label, 1-year treatment trial. RESULTS: Forty subjects were randomized to episodic therapy with valacyclovir (500 mg twice daily for 5 days) and 40 to suppressive therapy (500 mg daily). Subjects in the episodic arm experienced more outbreaks (7.87 ± 4.65) than those in the suppressive arm (1.59 ± 1.93) (P <0.001). Subjects in the episodic arm also had significantly more days with pain and lesions (6.5 ± 7.3) than those in the suppressive arm (1.1 ± 3.3) (P < 0.001), and other quantitative measures of disease burden also favored the suppressive arm. Both treatment groups had significant improvements in their recurrent genital herpes quality-of-life scores from baseline that persisted throughout the study; however, there was no significant difference between the treatment arms in these scores. CONCLUSIONS: Suppressive therapy of recurrent genital herpes with valacyclovir has a greater impact on measures of disease frequency and burden than episodic therapy. However, both treatment strategies lead to significant improvements in recurrent genital herpes quality-of-life scores. Both treatment strategies benefit patients with recurrent genital herpes.

AB - OBJECTIVES: We conducted this study to compare episodic and suppressive therapy for genital herpes about disease characteristics, disease burden, and psychologic impact. STUDY DESIGN: The authors conducted a randomized, open-label, 1-year treatment trial. RESULTS: Forty subjects were randomized to episodic therapy with valacyclovir (500 mg twice daily for 5 days) and 40 to suppressive therapy (500 mg daily). Subjects in the episodic arm experienced more outbreaks (7.87 ± 4.65) than those in the suppressive arm (1.59 ± 1.93) (P <0.001). Subjects in the episodic arm also had significantly more days with pain and lesions (6.5 ± 7.3) than those in the suppressive arm (1.1 ± 3.3) (P < 0.001), and other quantitative measures of disease burden also favored the suppressive arm. Both treatment groups had significant improvements in their recurrent genital herpes quality-of-life scores from baseline that persisted throughout the study; however, there was no significant difference between the treatment arms in these scores. CONCLUSIONS: Suppressive therapy of recurrent genital herpes with valacyclovir has a greater impact on measures of disease frequency and burden than episodic therapy. However, both treatment strategies lead to significant improvements in recurrent genital herpes quality-of-life scores. Both treatment strategies benefit patients with recurrent genital herpes.

UR - http://www.scopus.com/inward/record.url?scp=34248168818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248168818&partnerID=8YFLogxK

U2 - 10.1097/01.olq.0000237853.69443.71

DO - 10.1097/01.olq.0000237853.69443.71

M3 - Article

VL - 34

SP - 297

EP - 301

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 5

ER -